Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
GH-3 is an established cell line which, for the production of both PRL and GH, may be related to the bipotential somatomammotroph from which both somatotroph and mammotroph cells derive. In the present study we first report that GH-3 cells express both the gp140trk and the gp75 components of the nerve growth factor (NGF) receptor and that NGF dictates a nonneuronal type of differentiation of this cell line of ectodermal origin. After exposure to NGF, GH-3 cells markedly decreased their proliferation rate. This effect, which was maximal (50% inhibition) 3 days after beginning the treatment and was maintained during the following days of exposure, was paralleled by a change in the hormone production. The secretion of PRL was increased 6-fold, but that of GH was remarkably inhibited. Moreover, GH-3 cells expressed the mammotroph-specific D-2 receptor protein in response to NGF, as shown by binding with the D-2 receptor ligand N-(p-aminophenetyl)spiperone coupled to fluorescein. The present data thus show that NGF induces the differentiation of GH-3 cells into one of their physiological counterparts, the mammotroph cell, and together with the finding that NGF receptors are expressed in the anterior pituitary suggest a physiological role for the neurotrophic factor in pituitary ontogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor
Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., & Parada, L. F. (1991) · Science · doi:10.1126/science.1850549 · Cited by 1,379
Gene transfer and molecular cloning of the rat nerve growth factor receptor
Radeke, M. J., Misko, T. P., Hsu, C., Herzenberg, L. A., & Shooter, E. M. (1987) · Nature · doi:10.1038/325593a0 · Cited by 938
Hartikka, J., & Hefti, F. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02967.1988 · Cited by 317
Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression.
Spillantini, M. G., Aloe, L., Alleva, E., De Simone, R., Goedert, M., & Levi-Montalcini, R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8555 · Cited by 136
Cited by
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Self-citationProlactin: structure, function, and regulation of secretion
Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1523 · Cited by 2,457
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
“NGF treatment also induces the expression of D2R in GH3 cells (285).”
BackgroundNerve growth factor: from neurotrophin to neurokine
Levi-Montalcini, R., Skaper, S. D., Dal Toso, R., Petrelli, L., & Leon, A. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10058-8 · Cited by 686
The Cytogenesis and Pathogenesis of Pituitary Adenomas*
Asa, S. L., & Ezzat, S. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0350 · Cited by 388
Metadata
- Authors
- Missale, C.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1994-07-01
- Volume
- 135
- Issue
- 1
- Pages
- 290-298
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W1991170730
- Cited by
- 52
- References
- 4
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.